FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to compound of formula I: 
where Y1 and Y2 are independently selected from N and CR10, where R10 is selected from group, including hydrogen, halogen, C1-C6alkyl, halogen(C1-C6)alkyl, R1 is selected from group, including hydrogen, cyano, halogen, C1-C6alkyl, halogen(C1-C6)alkyl, C1-C6alkoxy, halogen(C1-C6)alkoxy, dimethylamino, C1-C6alkylsulfanyl, dimethylaminoethoxy and pyperasinyl, substituted up to 2 radicals C1-C6alkyl, R2 and R5 are independently selected from group, including hydrogen, cyano, halogen, C1-C6alkyl, halogen(C1-C6)alkyl, C1-C6alkoxy, halogen(C1-C6)alkoxy and dimethylamino, R3 and R4 are independently selected from group, including hydrogen, halogen, cyano, C1-C6alkyl, halogen(C1-C6)alkyl, C1-C6alkoxy, or R1 and R5 with phenyl, to which they are bound, form C5-C10heteroaryl, R6 and R7 are independently selected from group, including hydrogen, C1-C6alkyl, C1-C6alkoxy and halogen(C1-C6)alkyl, on condition that R6 and R7 both do not represent hydrogen, R8 is selected from group, including hydrogen, halogen, C1-C6alkyl, C1-C6alkoxy and halogen(C1-C6)alkoxy, R9 is selected from -S(O)2R11, -C(O)R11, -NR12aR12b and -R11, where R11 is selected from group, including aryl, cycloalkyl and heterocycloalkyl, R12a and R12b are independently selected from (C1-C6)alkyl and hydroxy(C1-C6)alkyl, and said aryl, heteroaryl, cycloalkyl and heterocycloalkyl in composition of R9 optionally contain as substituents from 1 to 3 radicals, independently selected from group, including (C1-C6)alkyl, halogen(C1-C6)alkyl, C1-C6alkoxy, halogen(C1-C6)alkoxy, C6-C10aryl(C0-C4)alkyl, C5-C10heteroaryl(C0-C4)alkyl, C3-C12cycloalkyl and C3-C8heterocycloalkyl, where said arylalkyl substituent in composition of R9 optionally contains as substituents from 1 to 3 radicals, independently selected from group, including halogen, cyano, (C1-C6)alkyl, halogen(C1-C6)alkyl, C1-C6alkoxy, halogen(C1-C6)alkoxy, dimethylamino and methyl-pyperasinyl, as well as to its pharmaceutically acceptable salts, hydrates, solvates and isomers. In addition, invention relates to method of inhibiting hedgehog pathway in cell and to method of inhibiting undesirable cell proliferation, when cell contacts with compound described above.
EFFECT: obtained and described are novel compounds, which can be applied in medicine.
13 cl, 153 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| USING SMOOTHENED ANTAGONISTS FOR TREATING HEDGEHOG PATHWAY RELATED DISORDERS | 2009 |
|
RU2519200C2 |
| COMPOUNDS AND COMPOSITIONS - HEDGEHOG SIGNALLING PATHWAY MODULATORS | 2007 |
|
RU2423354C2 |
| 2,5-DIOXOIMIDAZOLIN-4-YL METHYLCARBONYL COMPOUNDS, METHOD OF OBTAINING THEM, PHARMACEUTICAL MIXTURES CONTAING THEM AND THIR USE IN MEDICINE PREPARATION | 2003 |
|
RU2326117C2 |
| COMPOUNDS AND COMPOSITIONS AS CANNABINOID RECEPTOR 1 INHIBITORS | 2005 |
|
RU2431635C2 |
| ARYL AND HETEROARYLETHYLACTYLGUANIDINE, PREPARING AND USING THEM IN THERAPY | 2007 |
|
RU2446165C2 |
| DERIVATIVES OF BENZAMIDE, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 1999 |
|
RU2216541C2 |
| AMIDES OF 3-SUBSTITUTED 5- AND 6-AMINOALKYLINDOLE-2-CARBOXYLIC ACID AND RELATED ANALOGUES SUCH AS CASEIN KINASE IΕ INHIBITORS | 2005 |
|
RU2369599C2 |
| CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND USE THEREOF IN TREATING PSYCHOTIC DISORDERS | 2011 |
|
RU2586974C2 |
| GABA-ERGIC MODULATORS | 2004 |
|
RU2376292C2 |
| CARBOXAMIDE COMPOUNDS AND USING THEM AS CALPAIN INHIBITORS | 2010 |
|
RU2540856C2 |
